Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

647
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
647
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

154
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
154
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

538
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
538
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

192
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
192

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiology of Early-Onset Colorectal Cancer: A Systematic Review and Meta-Analysis of Incidence, Temporal Trends, and Associated Factors.

Cureus·2026
Same author

Left Atrial Appendage Closure vs. Oral Anticoagulation in Patients With Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal of arrhythmia·2026
Same author

Epidemiology and risk factors of surgical site infections in elective surgeries in Pakistan (2022-2023): a multicentre, prospective cohort study from PakSurg 1.

The Lancet regional health. Southeast Asia·2026
Same author

Early versus late oral anticoagulants after acute ischemic stroke in atrial fibrillation patients: a meta-analysis of randomized controlled trials.

Proceedings (Baylor University. Medical Center)·2026
Same author

Significant Left Atrial Appendage Leak After LAA Exclusion System Occluded by ASD Closure Device.

JACC. Case reports·2026
Same author

Metformin for COVID-19: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Reviews in medical virology·2026

Related Experiment Video

Updated: Jun 25, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.

Wajeeh Ur Rehman1, Merav Yarkoni1, Muhammad Abdullah Ilyas2

  • 1Heart and Vascular Institute, United Health Services, Johnson City, NY 13790, USA.

Journal of Cardiovascular Development and Disease
|May 24, 2024
PubMed
Summary

Cholesteryl-ester transfer-protein inhibitors (CETPis) reduce cardiovascular disease mortality and myocardial infarction risk. This meta-analysis confirms CETPis

Keywords:
CETP inhibitorsHDL-C lipoproteinsLDL-C lipoproteinsanacetrapibatherosclerosischolesterol ester transfer proteindalceprapibevacetrapibobicetrapibtorcetrapib

More Related Videos

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

29.8K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.3K

Related Experiment Videos

Last Updated: Jun 25, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K
Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

29.8K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.3K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Atherosclerosis is a complex disease driven by risk factors like LDL-C.
  • Cholesteryl-ester transfer-protein (CETP) regulates lipid levels, influencing LDL-C and HDL-C.
  • CETP inhibitors (CETPis) represent a novel therapeutic strategy for atherosclerotic cardiovascular disease (ASCVD).

Purpose of the Study:

  • To evaluate the efficacy of CETP inhibitors (CETPis) in reducing major adverse cardiovascular events (MACEs).
  • To investigate the impact of CETPis on cardiovascular disease (CVD)-related and all-cause mortality.
  • To synthesize findings from recent large-scale clinical trials on CETPis.

Main Methods:

  • Conducted a meta-analysis of randomized controlled trials (RCTs) published between 2003 and 2023.
  • Included studies comparing CETPi versus placebo with a minimum 6-month follow-up.
  • Analyzed outcomes including MACEs, CVD-related mortality, and all-cause mortality.

Main Results:

  • CETPi use significantly reduced CVD-related mortality (RR = 0.89; 95% CI: 0.81-0.98; p = 0.02).
  • CETPi use significantly reduced the risk of myocardial infarction (MI) (RR = 0.92; 95% CI: 0.86-0.98; p = 0.01).
  • These benefits were primarily attributed to anacetrapib; no significant effect on other outcomes was observed.

Conclusions:

  • This meta-analysis provides the first evidence that CETPis are associated with reduced CVD-related mortality.
  • CETP inhibitors demonstrate a significant reduction in myocardial infarction risk.
  • Further investigation into specific CETPis like anacetrapib is warranted for ASCVD risk reduction.